Lamotrigine (All indications)

Late intrauterine deaths (> 22 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8901
R30053		 AlSheikh (Lamotrigine), 2020 Stillbirth during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 0.38 [0.01;21.20] C 0/20   0/8 0 20
ref
S8904
R30084		 Aydin (Lamotrigine), 2020 Intrauterine fetal demise throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 3.31 [0.06;183.69] C 0/7   0/22 0 7
ref
S8972
R30409		 Holmes (Lamotrigine) (Mixed indications), 2011 Stillborn 1st trimester prospective cohort unexposed, disease free Adjustment: No 1.00 [0.05;20.96] C 2/948   0/190 2 948
ref
Total 3 studies 1.07 [0.13;8.49] 2 975
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF AlSheikh (Lamotrigine), 2020AlSheikh, 2020 1 0.38[0.01; 21.20]02027%ROB confusion: criticalROB selection: moderateROB classification: unclearROB missing: unclearROB mesure: moderateROB reporting: moderate Aydin (Lamotrigine), 2020Aydin, 2020 2 3.31[0.06; 183.69]0727%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Holmes (Lamotrigine) (Mixed indications), 2011Holmes, 2011 3 1.00[0.05; 20.96]294847%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 1.07[0.13; 8.49]29750.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine; 2: Lamotrigine; 3: Lamotrigine) (Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.07[0.13; 8.49]29750%NAAlSheikh (Lamotrigine), 2020 Aydin (Lamotrigine), 2020 Holmes (Lamotrigine) (Mixed indications), 2011 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.00[0.05; 20.96]2948 -NAHolmes (Lamotrigine) (Mixed indications), 2011 1 unexposed, sickunexposed, sick 1.13[0.07; 19.22]-270%NAAlSheikh (Lamotrigine), 2020 Aydin (Lamotrigine), 2020 2 Tags Adjustment   - No  - No 1.07[0.13; 8.49]29750%NAAlSheikh (Lamotrigine), 2020 Aydin (Lamotrigine), 2020 Holmes (Lamotrigine) (Mixed indications), 2011 3 All studiesAll studies 1.07[0.13; 8.49]29750%NAAlSheikh (Lamotrigine), 2020 Aydin (Lamotrigine), 2020 Holmes (Lamotrigine) (Mixed indications), 2011 30.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.05; 20.96]2948 -NAHolmes (Lamotrigine) (Mixed indications), 2011 1 unexposed, sick controlsunexposed, sick controls 1.13[0.07; 19.22]-270%NAAlSheikh (Lamotrigine), 2020 Aydin (Lamotrigine), 2020 20.510.01.0